8月4日，福泰制药盘中上涨3.05%，报481.47美元/股，成交额1.49亿美元。
消息面上，公司公布第二季度业绩：调整后每股收益4.73美元，同比增长4.65%，符合市场预期；营收33.34亿美元，同比增长12.5%，超出分析师预期的32.32亿美元约1亿美元。更为关键的是，公司将全年营收指引从此前的129.5亿至131亿美元上调至131亿至132亿美元，高于FactSet一致预期的130.6亿美元。
业绩公布后，Cantor Fitzgerald将目标价从590美元上调至595美元，维持增持评级。此前高盛亦将目标价上调至652美元。公司近期战略动作频繁，包括拟以100亿美元收购Crinetics拓展内分泌管线，以及Casgevy基因疗法获FDA扩展适用至两岁以上儿童，多重催化剂叠加支撑市场信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.